Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Genmab A/S - American Depositary Shares (NQ:GMAB)

33.52 +0.45 (+1.38%)
Streaming Delayed Price Updated: 2:46 PM EST, Dec 23, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Genmab A/S - American Depositary Shares

News headline image
2 Biotech Stocks to Buy for Outsized Gains ↗
Biotech companies’ success in responding to the COVID-19 pandemic by rapidly developing COVID-19 medicines and vaccines exemplified the sector’s importance and garnered significant investor attention. 
Via Talk Markets
News headline image
The Daily Biotech Pulse: Biogen Faces Another Clinical Setback, CureVac's COVID-19 Vaccine Study Fails, Moment Of Reckoning For Orphazyme ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 16) Alexion Pharmaceuticals,... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Merck Completes Organon Spin-Off, Auris Repositions As RNA Therapeutic Company With Trasir Purchase, Replimune's Readout ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 2) BioCryst Pharmaceuticals,... 
Via Benzinga
News headline image
Genmab and Bolt Biotherapeutics Announce Oncology Research and Development Collaboration
From Genmab A/S
Via Business Wire
News headline image
Genmab - Janssen's Darzalex Wins Positive Opinion In Europe For Two New Indications ↗
Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion and recommended granting marketing authorization to ... 
Via Benzinga
News headline image
Genmab A/S (GMAB) Q1 2021 Earnings Call Transcript ↗
GMAB earnings call for the period ending March 31, 2021. 
Via The Motley Fool
Topics Earnings
News headline image
Genmab and Seagen Announce U.S. FDA Filing Acceptance for Priority Review of Tisotumab Vedotin Biologics License Application for Patients with Recurrent or Metastatic Cervical Cancer
From Genmab A/S
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.